← All earnings call summaries
Glenmark Pharmaceuticals Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Gross margin impacted by geopolitical cost pressures; full-year margin guidance maintained at 21-22%
- India business growth guidance 12-15% with volume-led growth and new product launches
- Key priorities: US respiratory launches in H2 FY27, oncology launches Aumolertinib, Trastuzumab Rezetecan, envafolimab
- Consolidated revenue grew 23.1% Y-o-Y to INR40.2bn in Q1 FY27; base business up 18% excluding deferred income
- R&D spend around INR289cr in Q1; guided at 7-8% of sales; IGI pipeline progressing with multiple clinical trials
- Litigation provisions mostly done; no significant incremental cash outflows expected
- North America revenue up 41.1% Y-o-Y; core business growth 19.8%; 9 new product launches including respiratory
- India formulation sales grew 15.5% Y-o-Y; strong growth in dermatology, respiratory, cardiac, oncology
- Europe revenue grew 11.9%; branded respiratory and dermatology portfolio expanding
- Emerging markets revenue up 27.7%; strong growth in Russia, LATAM, MEA, APAC
📄 Source: View original transcript (PDF)
Get Glenmark Pharmaceuticals Limited earnings summaries on Telegram
Add Glenmark Pharmaceuticals Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.